Evotec SE

EVT

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    4,766

Stocks News & Analysis

stocks

2 ASX shares that benefit from sticky inflation

Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks

Our view of Dexus / Scentre deal

Dexus acquires stake in Westfiend Chermside.
stocks

Undervalued ASX retailer benefiting from rebound in spending

Uplift in sales momentum continues.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,917.5013.80-0.15%
CAC 408,068.6217.14-0.21%
DAX 4024,186.49108.12-0.45%
Dow JONES (US)48,458.05245.96-0.51%
FTSE 1009,649.0354.13-0.56%
HKSE25,763.85212.94-0.82%
NASDAQ23,195.17398.69-1.69%
Nikkei 22549,994.30842.25-1.66%
NZX 50 Index13,399.207.71-0.06%
S&P 5006,827.4173.59-1.07%
S&P/ASX 2008,628.6015.30-0.18%
SSE Composite Index3,884.934.41-0.11%

Market Movers